Screener
Monopar Therapeutics MNPR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 6,699 | 6,692 |
| Additional paid-in capital | 228,691,772 | 227,199,002 |
| Accumulated other comprehensive income (loss) | 98,521 | 131,389 |
| Retained earnings (accumulated deficit) | (93,402,580) | (89,509,530) |
| Total stockholders’ equity | 135,394,412 | 137,827,553 |
| Total liabilities and stockholders’ equity | $137,983,725 | $140,717,709 |
Document
FAQ
- What is Monopar Therapeutics's total equity?
- Monopar Therapeutics (MNPR) reported total equity of $135.39M in Q1 2026.
- How has Monopar Therapeutics's total equity changed year-over-year?
- Monopar Therapeutics's total equity increased by 152.6% year-over-year, from $53.59M to $135.39M.
- What is the long-term trend for Monopar Therapeutics's total equity?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total equity has grown at a 54.4% compound annual growth rate (CAGR), from $15.69M to $137.83M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Monopar Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude